Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2022 Mar 14;17(3):e0265196. doi: 10.1371/journal.pone.0265196

Effect of stimulation time on the expression of human macrophage polarization markers

Duygu Unuvar Purcu 1,2, Asli Korkmaz 1,3,#, Sinem Gunalp 1,3,#, Derya Goksu Helvaci 4, Yonca Erdal 1, Yavuz Dogan 5, Asli Suner 6, Gerhard Wingender 1,7, Duygu Sag 1,3,8,*
Editor: Alain Haziot9
PMCID: PMC8920204  PMID: 35286356

Abstract

Macrophages are highly plastic cells that can polarize into functionally distinct subsets in vivo and in vitro in response to environmental signals. The development of protocols to model macrophage polarization in vitro greatly contributes to our understanding of macrophage biology. Macrophages are divided into two main groups: Pro-inflammatory M1 macrophages (classically activated) and anti-inflammatory M2 macrophages (alternatively activated), based on several key surface markers and the production of inflammatory mediators. However, the expression of these common macrophage polarization markers is greatly affected by the stimulation time used. Unfortunately, there is no consensus yet regarding the optimal stimulation times for particular macrophage polarization markers in in vitro experiments. This situation is problematic, (i) as analysing a particular marker at a suboptimal time point can lead to false-negative results, and (ii) as it clearly impedes the comparison of different studies. Using human monocyte-derived macrophages (MDMs) in vitro, we analysed how the expression of the main polarization markers for M1 (CD64, CD86, CXCL9, CXCL10, HLA-DR, IDO1, IL1β, IL12, TNF), M2a (CD200R, CD206, CCL17, CCL22, IL-10, TGM2), and M2c (CD163, IL-10, TGFβ) macrophages changes over time at mRNA and protein levels. Our data establish the most appropriate stimulation time for the analysis of the expression of human macrophage polarization markers in vitro. Providing such a reference guide will likely facilitate the investigation of macrophage polarization and its reproducibility.

Introduction

Macrophages are phagocytes that play essential roles in both innate and adaptive immunity and are involved, for example, in host defence, regulation of metabolism, and tissue remodelling [13]. An essential feature of macrophages is their plasticity, whereby varying environmental signals can induce the differentiation of macrophages into functional distinct subsets [46]. Mirroring the Th1/Th2 paradigm, macrophages can polarize into classically activated M1 or alternatively activated M2 phenotypes [4, 7, 8]. Although the M1/M2 dichotomy appears to be a simplification of the in vivo situation, it is a helpful experimental distinction that greatly contributed to our understanding of macrophage biology [9].

M1 macrophages are proinflammatory cells that display anti-tumour and anti-microbial activities [10, 11]. M1 activation is induced by IFNγ alone or in combination with LPS or TNF [8, 12]. M1 macrophages secrete large amounts of pro-inflammatory cytokines such as TNF, IL-1β, IL-6, IL-12, and IL-23, as well as chemokines like CXCL9 and CXCL10. They also express MHC class II (e.g. HLA-DR in humans) and costimulatory molecules including CD80 and CD86 [1315]. In addition, M1 macrophages upregulate the expression of the tryptophan catabolizing enzyme IDO1 and of SOCS3, a suppressor of M2 cytokine signaling [8, 16].

M2 macrophages are anti-inflammatory cells that play a role in angiogenesis, wound healing, and tissue remodelling [17, 18]. M2 macrophages can further be divided into M2a, M2b, M2c, and M2d subtypes [14, 19, 20]. M2a macrophages can be induced by IL-4 and/or IL-13 and they express CD206 (MRC1), CD200R, the decoy receptor IL-1RII, TGM2 (transglutaminase 2) and the chemokines CCL17, CCL22 and CCL24. M2b macrophages can be induced by immune complexes, and TLR agonists, or IL-1 receptor ligands and they can express IL-6, IL-10, IL-1β, and TNF [12, 20, 21]. M2c macrophages can be induced by IL-10, glucocorticoids, or TGFβ and express CD163, IL-10, and TGFβ [12, 22]. Finally, M2d macrophages can be induced by TLR agonists or adenosine receptor activation and they express IL-10, IL-12, TGFβ, and TNF [23, 24].

Significant differences between mice and humans for the expression of macrophage polarization markers have been noted. For instance, while murine M1 macrophages express inducible NO synthase (iNOS), which is involved in L-arginine metabolism, human M1 macrophages do not [25]. Moreover, murine M2a macrophages induced by IL-4 and/or IL-13 express Arg1, Ym1, and Fizz1, but these genes do not have human homologs [14, 19, 26, 27]. Due to these differences, it is unclear to which extent data on murine M1/M2 polarization mimic human macrophage biology. Although monocytic cell lines such as THP-1 are commonly used for human macrophage studies, these cells display some substantial differences compared to primary human macrophages [28]. For example, PMA-treated THP-1 macrophage-like cells do not express HLA-DR and CD206 but show higher expression of CD14 and IL-1β compared to primary human macrophages [29]. Furthermore, it was reported that the response to LPS stimulation by THP-1 cells is weaker than by primary cells [30] and the expression of CD14 and cytokines by THP-1 cells was sensitive to the culture conditions such as the cell density [31]. Therefore, experiments using primary human macrophages are most suitable to understand macrophage polarization in humans.

While there is largely agreement on which markers are best for the analysis of macrophage polarization [8, 15, 24, 32], this is not the case for the optimal time point to do so. However, the consideration of the stimulation time is important as the expression of common macrophage polarization markers greatly changes over time. This leads to the unfortunate situation that many studies report on the inability of a particular macrophage subset to respond, that may well be false negative data as a suboptimal time point for the analysis was chosen. This lack of consensus on the optimal stimulation time of each polarization marker, greatly complicates the comparison of different studies and their findings. However, to our best knowledge, no comprehensive time course analysis of the common polarization markers has been published. Here we report a detailed time course of the expression of the main M1, M2a, and M2c polarization markers of human monocyte-derived macrophages (MDMs) in vitro at both mRNA and protein levels. Our data establish the optimal time points for the analysis of the expression of these polarization markers, which will greatly facilitate their investigation.

Materials and methods

Generation of human monocyte-derived macrophages (MDMs)

The ethical approval for buffy coats was obtained from the “Non-Interventional Research Ethics Committee” of the Dokuz Eylül University (Approval number: 2019/02-39). The buffy coats from healthy donors were obtained from the Dokuz Eylul University Blood Bank (Izmir, Turkey) after written consent. Human monocytes were purified from buffy coats by two gradient centrifugations: PBMCs were initially isolated with Ficoll-Paque (GE Healthcare, Pittsburgh, PA) and subsequently peripheral monocytes were isolated with Percoll (GE Healthcare, Pittsburgh, PA) [33]. To generate human monocyte-derived macrophages (MDMs), monocytes were treated for 7 days with 10 ng/mL human recombinant M-CSF (PeproTech, Rocky Hill, NJ) in R5 medium (RPMI 1640 (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 5% heat inactivated fetal bovine serum (Gibco, Thermo Fisher Scientific, Waltham, MA, USA), 1% Penicillin-Streptomycin (Gibco, Thermo Fisher Scientific, Waltham, MA, USA)) in ultra-low attachment six-well plates (Corning Life Sciences, Tewksbury, MA) [34]. On day 7, the mature macrophages were collected from the low attachment plates and verified to be more than 90% CD68+ by flow cytometry.

Polarization of human MDMs

Human MDMs were plated in 24 well plates at 6.5 x 105 cells per well in 1 mL R5 medium and allowed to rest overnight at 37°C before stimulation. Then, the human MDMs (M0 macrophages) were either left unstimulated or stimulated for 4h, 8h, 12h, 24h, 48h, or 72 h to induce macrophage polarization: (i) for M1 polarization with 100 ng/mL LPS (Ultrapure; InvivoGen, San Diego, CA) and 20 ng/mL IFNγ (R&D, Minneapolis, MN), (ii) for M2a polarization with 20 ng/mL IL-4 (R&D, Minneapolis, MN), or (iii) for M2c polarization with 20 ng/mL IL-10 (R&D, Minneapolis, MN). The viability of the LPS+ IFNγ treated human MDMs was analyzed by flow cytometry and was over 92% for all time points.

ELISA

After stimulations, supernatants were collected and TNF (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA), IL-12 (BioLegend, San Diego, CA), IL-10 (BioLegend, San Diego, CA), IL-1β (BioLegend, San Diego, CA), and TGFβ (R&D, Minneapolis, MN) concentrations were determined by ELISA according to the manufacturer’s instructions.

Quantitative real time PCR

Total RNA of macrophages was isolated using the Nucleo-Spin RNA kit (Macharey Nagel, Germany). RNA purity and quantity were evaluated with Nanodrop spectrophotometer (Thermo Scientific, Rockford, IL). cDNA synthesis was performed using EvoScript Universal cDNA Master, using 1000 ng of RNA per sample (Roche, Basel, Switzerland). Quantitative PCR (qPCR) was performed with a LightCycler 480 II real time system (Roche, Basel, Switzerland) using FastStart Essential DNA Probes Master (Roche, Basel, Switzerland) and the following RealTime ready Single Assays (Roche, Basel, Switzerland) for IDO1 (100134768), CXCL10 (100134759), TNF (100134777), CXCL9 (100137998), MRC1 (100134731), TGM2 (100134722), CCL17 (100138007), CCL22 (100134713), IL-10 (100133437), CD163 (100134801), and ACTB (100074091). qPCR for the markers below was performed with Applied Biosystems™ 7500 Real-Time PCR System (Waltham, Massachusetts, USA) using FastStart Essential DNA Green Master (Roche, Basel, Switzerland) and the following QuantiTect Primer Assay (Qiagen, Düsseldorf, Germany) for IL1β (QT00021385), IL12A (QT00000357), IL-10 (QT00041685), TGFβ (QT00000728) and ACTB (QT00095431). RNA isolation, cDNA synthesis, and the quantitative PCR were performed according to the manufacturers’ recommendations. Relative mRNA expression was calculated using the 2-ΔΔCt method [35] and β-actin was used for normalization as housekeeping gene.

Flow cytometry

Macrophages were detached from the cell plate surface using StemPro Accutase Cell Dissociation Reagent (Gibco; Thermo Fisher Scientific, Waltham, MA, USA) according to manufacturer’s instructions. Single-cell suspensions were stained in flow cytometry staining buffer (PBS, 1% bovine serum albumin, 0.1% sodium azide). Zombie UV Fixable Viability Kit (BioLegend, San Diego, CA, USA) was used to determine cell viability. Fcγ receptors were blocked with Human TruStain FcX antibody (BioLegend, San Diego, CA) for 10 min and surface antigens on cells were stained for 40 min at 4°C. Following anti-human antibodies were used, with their fluorochrome, clone, and dilution: CD86-BV605 (IT2.2; 1:400), HLA-DR-APC-Cy7 (L243; 1:400), CD64-PerCP-Cy5.5 (10.1; 1:200), CD200R-PE-Dazzle594 (OX-108; 1:400), CD206-AF700 (15–2; 1:400), CD163-PE-Cy7 (GHI/61; 1:200). Antibodies were purchased from BioLegend (San Diego, CA, USA). Cell fluorescence was measured using an LSR Fortessa (BD Biosciences) and the data were analyzed with FlowJo software (TreeStar, Ashland, OR). Forward- and side-scatter parameters were used to exclude doublets from the analysis.

Statistical analysis

Results are expressed as mean ± SEM. A repeated measures ANOVA with a post hoc test, Least Significant Difference (LSD) adjustment, was used to compare group means of experimental data at each time point. The p-values were calculated by two-tailed and less than 0.05 was considered statistically significant. Statistical analyses were performed using IBM SPSS version 25.0 statistical software. All graphs were generated using Graph Pad Prism 8 (GraphPad Software, CA, USA).

Results

Time course dependent changes in the expression of polarization markers at mRNA level in M1, M2a, and M2c macrophages

To establish the optimum stimulation times for the expression of the common markers used to identify M1/M2 macrophage subtypes [20, 32, 3638], primary human monocyte-drived macrophages (MDMs) were first analyzed at the mRNA level. Primary human MDMs were polarized into an M1 (100 ng/mL LPS, 20 ng/mL IFNγ), an M2a (20 ng/mL IL-4), or an M2c (20 ng/mL IL-10) phenotype for 4, 8, 12, 24, 48, or 72 h. The expression of M1, M2a, or M2c markers was analyzed at mRNA level by qPCR. Unpolarized human MDMs were used as control. In M1 macrophages, the mRNA expression of the M1 markers CXCL9, CXCL10, and TNF reached their highest level after 4 h of stimulation with a gradually decrease thereafter (Fig 1A–1C). The expression of IL-1β sigificantly increased at 4 h of stimulation and the level of expression stayed stable at later time points (Fig 1D). Unlike the other M1 cytokines, IL-12 gene expression decreased below basal level after 4 h and significantly increased starting 48 h (Fig 1E). In contrast, the IDO1 expression in M1 macrophages continuously increased during the time course reaching its highest value at 48–72 h (Fig 1F).

Fig 1. Time depended changes in the expression of macrophage polarization markers at mRNA level.

Fig 1

Primary human MDMs (M0) were left unstimulated or were polarized to M1 (100 ng/mL LPS, 20 ng/mL IFNγ), M2a (20 ng/mL IL-4), or M2c (20 ng/mL IL-10) for 4, 8, 12, 24, 48, or 72 h. The expression of (A-F) CXCL9, CXCL10, TNF, IL-1β, IL-12, and IDO1 mRNA for M1 polarization; of (G-K) MRC1, TGM2, CCL17, CCL22 and IL-10 mRNA for M2a polarization; and of (L-N) IL-10, CD163 and TGFβ mRNA for M2c polarization were analyzed by qPCR. Data shown are mean ± SEM of biological replicates of 3 independent donors. Polarized macrophages (M1, M2a, or M2c) at all time points were compared with unstimulated (US) M0 macrophages. Trends for individual donors are depicted in S1 Fig. Statistical analyses were performed with repeated measures ANOVA, * p < 0.05; ** p < 0.01; *** p < 0.001 (Statistical comparison of all time points are shown in the S1 Table).

In M2a macrophages, the M2a markers MRC1 (CD206) and TGM2 were induced after 4 h without major changes until the 48 h time point. A further increase for both was noted at 72 h (Fig 1G and 1H). Compared to the other M2a markers, CCL17 expression was very high at all time points (Fig 1I). The expression of CCL22 in M2a macrophages gradually increased from 4h to 48h (Fig 1J). Surprisingly, IL-10 expression gradually decreased below baseline between 4–72 h (Fig 1K). In M2c macrophages, the M2c markers IL-10, CD163 and TGFβ were analyzed. The expression of IL-10 mRNA peaked at 4h (Fig 1L), whereas the expression of CD163 mRNA was comparable between 4 h and 72 h (Fig 1M). We did not observe TGFβ gene expression at any time points analyzed (Fig 1N).

As donor-donor variability in human macrophages has been reported [39, 40], we also graphed the changes of the expression of the analyzed polarization markers over time for each donor separately (S1S3 Figs) to illustrate the observed variability.

These data indicate that 4–8 h is the optimal stimulation time for the simultaneous detection of the M1 markers, at the mRNA level. While for M2c markers, except TGFβ, 4 h of stimulation seems ideal; M2a markers, except IL-10, can be simultaneously detected between 8–72 h of stimulation (Table 1).

Table 1. Suggested stimulation times for the detection of M1, M2a, and M2c polarization markers in human monocyte-derived macrophages.

Macrophage Phenotype Stimulant Detection Method Marker Type Suggested Stimulation Time for Optimal Detection
M1 LPS + IFNγ qPCR CXCL9 Chemokine 4–8 h
CXCL10 Chemokine 4–8 h
TNF Cytokine 4–8 h
IL-1β Cytokine 4–72 h
IL-12 Cytokine 4 h, 48–72 h
IDO1 Enzyme 4–72 h
Flow Cyt. CD86 Co-stimulatory M. 8–12 h
CD64 Fc Receptor 24–72 h
HLA-DR MHC class II M. 12 h
ELISA TNF Cytokine 4–72 h
IL12p70 Cytokine 8–72 h
IL-1β Cytokine 8–24 h
M2a IL-4 qPCR MRC1 Mannose R. 4–72 h
TGM2 Enzyme 4–72 h
CCL17 Chemokine 4–72 h
CCL22 Chemokine 8–72 h
IL-10 Cytokine nd
Flow Cyt. CD200R Inhibitory R. 24–72 h
CD206 Mannose R. 24–72 h
ELISA IL-10 Cytokine 48–72 h
M2c IL-10 qPCR IL-10 Cytokine 4 h
CD163 Scavenger R. 4–72 h
TGFβ Cytokine nd
Flow Cyt. CD163 Scavenger R. 24–72 h
ELISA TGFβ Cytokine 72h

Flow Cyt., flow cytometry; R, receptor; P, protein; M, molecule; nd, no significant upregulation was detected.

Time course depended changes in the expression of surface markers at protein level in M1, M2a and M2c macrophages

Next, to determine the impact of stimulation time on the expression of surface markers, the primary human MDMs were analyzed for the expression of M1, M2a or M2c surface markers by flow cytometry (Fig 2, S2 Fig). In human MDMs polarized into an M1 phenotype, the CD86 expression was, surprisingly, bimodal, with peaks after 12 h and 72 h of stimulation and at background levels at the 24 h time point (Fig 2A). The CD64 expression was increased from 8 h to 72 h (Fig 2B). The expression of HLA-DR was significantly enhanced only at 12 h (Fig 2C).

Fig 2. Time depended changes in the expression of macrophage polarization markers at protein level.

Fig 2

Primary human MDMs (M0) were left unstimulated or were polarized to M1 (100 ng/mL LPS, 20 ng/mL IFNγ) or M2a (20 ng/mL IL-4) for 4, 8, 12, 24, 48, or 72 h. Surface marker expression (A-C) of CD86, CD64 and HLA-DR for M1 polarization; (D-E) of CD200R and CD206 (MRC1) for M2a polarization, and (F) of CD163 for M2c polarization was analyzed by flow cytometry. Shown are representative histograms (left) and summary data shown are mean ± SEM of biological replicates of 3 independent donors (right). Polarized macrophages (M1, M2a, or M2c) at all time points were compared with unstimulated (US) M0 macrophages. Trends for individual donors are depicted in S2 Fig. Statistical analyses were performed with repeated measures ANOVA, * p < 0.05; ** p < 0.01; *** p < 0.001 (Statistical comparison of all time points are shown in the S2 Table).

In M2a polarized macrophages, the expression of CD200R and CD206 (MRC1) was significantly increased starting from 8h of stimulation with the highest levels reached after 48–72 h (Fig 2D and 2E). In M2c polarized macrophages, although the expression of CD163 was increased after 24 h of stimulation, it did not reach statistical significance (Fig 2F). This seems to be due to the variation between donors (S2 Fig).

To test if the M2a and M2c surface markers were specific to these subtypes, the expression of the M2 markers were analyzed in M1, M2a, and M2c macrophages by flow cytometry. The strong upregulation of CD206 on M2a macrophages was not seen on M1 or M2c macrophages. Moreover, the expression of the M2c marker CD163 was not increased on M1 and M2a macrophages (S4 Fig). This confirms that the selected M2 markers were appropriate to identify their respective macrophage subtype.

These data indicate that 12 h of stimulation is best for the M1 surface markers CD86 and HLA-DR, whereas 24–72 h of stimulation is needed for the M1 marker CD64 and the M2 markers CD200R, CD206, and CD163 (Table 1).

Time course depended changes in cytokine production by M1, M2a and M2c macrophages

Finally, the production of key cytokines by the M1, M2a, or M2c polarized human MDMs was analyzed by ELISA (Fig 3, S3 Fig). TNF production by M1 macrophages peaked at 4, 8, and 12 h of stimulation, with a slight decrease at later time points (Fig 3A). IL-12 production was low at 4 h but prominent and stable between 8 h to 72 h of stimulation (Fig 3B). In contrast, IL-1β production by M1 macrophages was significantly increased between the 8 h-24 h time points (Fig 3C). In M2 macrophages, a significant production of cytokines was only observed after 48 h (IL-10) and 72 h (IL-10, TGFβ) of stimulation (Fig 3D and 3E).

Fig 3. Time depended changes in cytokine production by M1, M2a, and M2c macrophages.

Fig 3

Primary human MDMs (M0) were left unstimulated or were polarized to M1 (100 ng/mL LPS, 20 ng/mL IFNγ), M2a (20 ng/mL IL-4), or M2c (20 ng/mL IL-10) for 4, 8, 12, 24, 48, or 72 h. Production of (A-C) TNF, IL-12 and IL-1β for M1 polarization; of (D) IL-10 for M2a polarization, and of (E) TGFβ for M2c polarization was analyzed by ELISA. Data shown are mean ± SEM of biological replicates of 3 independent donors. Polarized macrophages (M1, M2a, or M2c) at all time points were compared with unstimulated (US) M0 macrophages. Trends for individual donors are depicted in S3 Fig. Statistical analyses were performed with repeated measures ANOVA, * p < 0.05; ** p < 0.01; *** p < 0.001 (Statistical comparison of all time points are shown in the S3 Table).

These data indicate that 8–24 h of stimulation is best for the simultanious detection of the M1 cytokines IL-1β, IL-12p70, and TNF, whereas 72 h of stimulation is needed for the detection of the M2 cytokines IL10 and TGFβ, simultaneously (Table 1).

Discussion

Macrophages can polarize into different functional phenotypes according to the signals they receive from the environment. Environmental signals that induce macrophage polarization in vivo can be mimicked in in vitro studies [5, 6, 41]. Although the stimulation time affects the expression levels of most markers used to analyze M1 and M2 polarization, there is no consensus in the literature regarding the timing to analyze particular markers during in vitro experiments. Here we report a detailed time course of M1, M2a, and M2c polarization markers of primary human macrophages that determine the optimal time points for their detection at mRNA and protein levels.

Our results demonstrate a dramatic increase in the expression of the chemokines CXCL9 and CXCL10 and the cytokine TNF at mRNA level in the first 4 h of stimulation of primary MDMs polarized into the M1 phenotype with LPS-IFNγ (Fig 1A–1C). In M1 polarization, the upward trend in gene expression decreased with prolonged stimulation, for these genes. Interestingly, in contrast to the other M1 markers tested, IDO1 expression was increased with prolonged stimulation, reaching its highest value between 48 and 72 h (Fig 1F). Since IDO1 is a regulatory enzyme, that is induced after inflammation [42], it is understandable that it is induced later than cytokines and chemokines. Our results are in accordance with previous studies, in which macrophages were stimulated for 48 h to determine IDO1 expression [43, 44]. Based on our results, 4 h LPS-IFNγ stimulation, seems to be the optimum time point to observe the changes in M1 markers at mRNA level. Although IDO1 mRNA expression peaked at late stimulation points, its expression was also quite high at 4 h of stimulation (Fig 1F). In M2a macrophages, CCL17 expression was high at all time points studied, while CCL22 expression was increased from 4 h to 48 h of stimulation (Fig 1I and 1J).

The surface markers CD64, CD86, and HLA-DR are commonly used as M1 polarization markers [19]. In our study, the expression of CD86 and HLA-DR on M1 macrophages showed the strongest increase at the 12 h time point followed by a decrease at 24–72 h (Fig 2A and 2C), similar to previous studies [45]. Stimulation of macrophages with LPS leads to the production IL-10 that inhibits CD86 in an autocrine manner to prevent overexpression of CD86 [46]. Therefore, the observed decrease in CD86 and HLA-DR could be due to the down-regulation of these receptors by IL-10 [4648]. It has been reported that CD86 expression is higher in both M1 and M2 macrophages than unpolarized MDMs at 48 h [45], and 72 h [13] of stimulation. Based on our results, the optimum stimulation time for CD86 and HLA-DR to be considered as M1 polarization markers is 12 h, and their expression on M1 macrophages decreases thereafter. In contrast, CD64 expression on M1 macrophages was increased from 8 h to 72 h of stimulation (Fig 2B), unlike HLA-DR and CD86 expression. CD64 expression has been reported to be consistently high on M1 macrophages over a wide range of stimulation times [13, 41, 49]. CD64 has been defined as one of the most distinctive M1 polarization markers [41].

While CD206 is a recognized M2a marker for murine macrophages [50], some studies suggested that it was not a specific marker for M2a polarization in humans. [49, 51]. It has been reported that MDMs polarized into M2a phenotype for 24 h, upregulated CD200R but not CD206 [51]. According to our results, the expression of the surface markers CD200R and CD206 gradually increased over time in human MDMs polarized into M2a with IL-4, reaching a maximum level at 48 and 72 h of stimulation (Fig 2D and 2E). Expression of the mannose receptor CD206 (MRC1) at mRNA level also peaked at 72 h of stimulation in M2a macrophages (Fig 1G). Furthermore, the strong upregulation of CD206 on M2a macrophages was not seen on M1 or M2c macrophages, confirming that CD206 is specific to M2a polarization. (S4 Fig).

The scavenger receptor CD163 is a specific M2c polarization marker (Vogel et al., 2014). In our study, the surface CD163 expression on IL-10 stimulated M2c macrophages was increased after 24–72 h of stimulation (Fig 2F), which is consistent with the previous studies [41, 45, 49]. However, it did not reach statistical significance, which seems to be due to donor variability (S2 Fig). In M2c macrophages, CD163 gene expression was increased at 4 h and onwards (Fig 1M), in accordance with this, CD163 surface marker expression peaked at later hours as expected (Fig 2F).

We also examined the impact of time on the cytokine production and gene expression levels of polarized MDMs. The production of IL-1β, IL12p70, and TNF was high after a wide range of stimulation times in M1 macrophages with 8–12 h of stimulation being optimal (Fig 3A–3C). A previous study has reported TNF and IL12p40 production in M1 macrophages after 48 h of stimulation, while no IL-1β production was detected [41]. In M1 macrophages, IL-12 gene expression was increased at 4 h of stimulation (Fig 1E); which was mirrored by an increase of IL-12 production after 4 h (Fig 3B). The increase in gene expression at 4 h was followed by a decrease below basal level starting from 8 h and another increase after 48 h. It has been shown that the transcription factor IRF5 remains bound to the IL12 promoter for 16 hours after LPS stimulation. The binding peaks at the 4th hour of stimulation and then decreases [52]. Decreased IRF5 binding may account for the fluctuation in IL-12 gene expression in our results. In M1 polarization, the increase of IL-1β gene expression at 4 h of stimulation triggered IL-1β production at 8–24 h of stimulation (Fig 1D). Contrary to the increase in IL-10 gene expression in M2c macrophages (Fig 1L), the gene expression of IL-10 was decreased below basal level in M2a macrophages (Fig 1K). In line with our finding, it was reported that M2a (IL-4) stimulation did not trigger IL-10 gene expression in bone-marrow derived macrophages after 24-hour stimulation [53]. In contrast, however, THP-1 cells displayed enhanced IL-10 expression after 24 hours of M2a (IL-4) stimulation [54]. These differing results may be due to the different response of primary macrophages and cell lines. Although IL-10 gene expression was not increased in M2a macrophages (Fig 1K), IL-10 production was observed after 48 h (Fig 3D). In M2c macrophages, TGFβ gene expression was not detectable at any time of stimulation but prominent TGFβ production was observed at 72 h of stimulation (Fig 3E). Although one would expect that an increase at the protein level follows an increase at mRNA level, this is not always the case, as current mRNA expression could suffice to maintain protein expression [55] or as protein accumulates for later release [56, 57].

In summary, we report here the optimal time points for the analysis of the expression of the main M1, M2a, and M2c polarization markers. It is unfortunate that there is no consensus yet regarding the optimal stimulation times for particular macrophage polarization markers in in vitro experiments, as this can lead to false-negative results and impedes the comparison of different studies. Therefore, our study provides useful guideline for the optimal polarization times of primary human macrophages, which will likely facilitate the investigation of macrophage polarization and its reproducibility.

Supporting information

S1 Table. Statistical analyses for M1, M2a and M2c markers at mRNA level in polarized macrophages.

Expression of the indicated markers at the time points shown were compared by repeated measures ANOVA, * p < 0.05; ** p < 0.01; *** p < 0.001. ns, not significant; US, unstimulated.

(PDF)

S2 Table. Statistical analyses for M1, M2a and M2c surface markers in polarized macrophages.

Expression of the indicated markers at the time points shown were compared by repeated measures ANOVA, * p < 0.05; ** p < 0.01; *** p < 0.001. ns, not significant; US, unstimulated.

(PDF)

S3 Table. Statistical analyses for M1, M2a and M2c cytokines in polarized macrophages.

Expression of the indicated markers at the time points shown were compared by repeated measures ANOVA, * p < 0.05; ** p < 0.01; *** p < 0.001. ns, not significant; US, unstimulated.

(PDF)

S1 Fig. Time-dependent changes in the expression of macrophage polarization markers at the mRNA level for each donor.

(TIF)

S2 Fig. Time-dependent changes in the expression of macrophage polarization markers at the protein level for each donor.

(TIF)

S3 Fig. Time-dependent changes in cytokine production for each donor.

(TIF)

S4 Fig. Time depended changes in the expression of M2 markers in M1, M2a and M2c macrophages analysed by flow cytometry.

Summary data shown are mean ± SEM of biological replicates of 3 independent donors. Polarized macrophages (M1, M2a, or M2c) at all time points were compared with unstimulated (US) M0 macrophages. Statistical analyses were performed with repeated measures ANOVA, * p < 0.05; ** p < 0.01; *** p < 0.001.

(TIF)

Acknowledgments

We thank Dr. Safiye Nese Atabey and Dr. Mehtap Yuksel Egrilmez for valuable scientific contributions. We thank the Flow Cytometry and Cell Sorting Facility at the Izmir Biomedicine and Genome Center for excellent technical assistance.

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

This work was funded by the Co-Funded Brain Circulation Scheme (MSCA/TUBITAK, #115C074), www.tubitak.gov.tr; the Dokuz Eylul University (#2017.KB.SAG.011), https://www.deu.edu.tr; the Turkish Academy of Sciences (TUBA-GEBIP award), http://www.tuba.gov.tr/tr/; and the Science Academy, Turkey (BAGEP award), https://bilimakademisi.org/ (all to D.S). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Stout RD, Suttles J. Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J Leukoc Biol. 2004;76: 509–513. doi: 10.1189/jlb.0504272 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8: 958–969. doi: 10.1038/nri2448 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature. Nature Publishing Group; 2013. pp. 445–455. doi: 10.1038/nature12034 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11: 889–896. doi: 10.1038/ni.1937 [DOI] [PubMed] [Google Scholar]
  • 5.Sica A, Mantovani A. Macrophage plasticity and polarization: In vivo veritas. Journal of Clinical Investigation. American Society for Clinical Investigation; 2012. pp. 787–795. doi: 10.1172/JCI59643 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Akira S, Misawa T, Satoh T, Saitoh T. Macrophages control innate inflammation. Diabetes, Obesity and Metabolism. Blackwell Publishing Ltd; 2013. pp. 10–18. doi: 10.1111/dom.12151 [DOI] [PubMed] [Google Scholar]
  • 7.Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000;164: 6166–73. Available: http://www.ncbi.nlm.nih.gov/pubmed/10843666 doi: 10.4049/jimmunol.164.12.6166 [DOI] [PubMed] [Google Scholar]
  • 8.Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014;6: 13. doi: 10.12703/P6-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Locati M, Curtale G, Mantovani A. Diversity, Mechanisms, and Significance of Macrophage Plasticity. Annu Rev Pathol Mech Dis. 2020;15: 123–147. doi: 10.1146/annurev-pathmechdis-012418-012718 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, et al. Macrophage polarization in tumour progression. Seminars in Cancer Biology. 2008. pp. 349–355. doi: 10.1016/j.semcancer.2008.03.004 [DOI] [PubMed] [Google Scholar]
  • 11.Atri C, Guerfali FZ, Laouini D. Role of human macrophage polarization in inflammation during infectious diseases. International Journal of Molecular Sciences. MDPI AG; 2018. doi: 10.3390/ijms19061801 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci. 2008;13: 453–61. doi: 10.2741/2692 [DOI] [PubMed] [Google Scholar]
  • 13.Beyer M, Mallmann MR, Xue J, Staratschek-Jox A, Vorholt D, Krebs W, et al. High-Resolution Transcriptome of Human Macrophages. Zirlik A, editor. PLoS One. 2012;7: e45466. doi: 10.1371/journal.pone.0045466 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Wang N, Liang H, Zen K. Molecular mechanisms that influence the macrophage M1-M2 polarization balance. Frontiers in Immunology. Frontiers; 2014. p. 614. doi: 10.3389/fimmu.2014.00614 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression. J Immunol. 2006;177: 7303–7311. doi: 10.4049/jimmunol.177.10.7303 [DOI] [PubMed] [Google Scholar]
  • 16.Wilson HM. SOCS proteins in macrophage polarization and function. Frontiers in Immunology. Frontiers Research Foundation; 2014. doi: 10.3389/fimmu.2014.00357 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Gordon S. Alternative activation of macrophages. Nature Reviews Immunology. Nature Publishing Group; 2003. pp. 23–35. doi: 10.1038/nri978 [DOI] [PubMed] [Google Scholar]
  • 18.Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol. 2013;229: 176–185. doi: 10.1002/path.4133 [DOI] [PubMed] [Google Scholar]
  • 19.Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in Immunology. 2002. pp. 549–555. doi: 10.1016/s1471-4906(02)02302-5 [DOI] [PubMed] [Google Scholar]
  • 20.Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends in Immunology. Oxford University Press, Oxford; 2004. pp. 677–686. doi: 10.1016/j.it.2004.09.015 [DOI] [PubMed] [Google Scholar]
  • 21.Wang L xun, Zhang S xi, Wu H juan, Rong X lu, Guo J. M2b macrophage polarization and its roles in diseases. Journal of Leukocyte Biology. John Wiley and Sons Inc.; 2019. pp. 345–358. doi: 10.1002/JLB.3RU1018-378RR [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Huang X, Li Y, Fu M, Xin HB. Polarizing macrophages in vitro. Methods in Molecular Biology. Humana Press Inc.; 2018. pp. 119–126. doi: 10.1007/978-1-4939-7837-3_12 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili SA, Mardani F, et al. Macrophage plasticity, polarization, and function in health and disease. Journal of Cellular Physiology. Wiley-Liss Inc.; 2018. pp. 6425–6440. doi: 10.1002/jcp.26429 [DOI] [PubMed] [Google Scholar]
  • 24.Rőszer T, Roszer T. Understanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms. Mediators Inflamm. 2015;2015: 1–16. doi: 10.1155/2015/816460 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Murray PJ, Wynn TA. Obstacles and opportunities for understanding macrophage polarization. J Leukoc Biol. 2011;89: 557–563. doi: 10.1189/jlb.0710409 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Gordon S, Martinez FO. Alternative activation of macrophages: Mechanism and functions. Immunity. 2010;32: 593–604. doi: 10.1016/j.immuni.2010.05.007 [DOI] [PubMed] [Google Scholar]
  • 27.Mantovani A, Locati M. Tumor-associated macrophages as a paradigm of macrophage plasticity, diversity, and polarization lessons and open questions. Arterioscler Thromb Vasc Biol. 2013;33: 1478–1483. doi: 10.1161/ATVBAHA.113.300168 [DOI] [PubMed] [Google Scholar]
  • 28.Tarique AA, Logan J, Thomas E, Holt PG, Sly PD, Fantino E. Phenotypic,functional,and plasticity features of classical and alternatively activated human macrophages. Am J Respir Cell Mol Biol. 2015;53: 676–688. doi: 10.1165/rcmb.2015-0012OC [DOI] [PubMed] [Google Scholar]
  • 29.Kohro T, Tanaka T, Murakami T, Wada Y, Aburatani H, Hamakubo T, et al. A comparison of differences in the gene expression profiles of phorbol 12-myristate 13-acetate differentiated THP-1 cells and human monocyte-derived macrophage. J Atheroscler Thromb. 2004;11: 88–97. doi: 10.5551/jat.11.88 [DOI] [PubMed] [Google Scholar]
  • 30.Schildberger A, Rossmanith E, Eichhorn T, Strassl K, Weber V. Monocytes, peripheral blood mononuclear cells, and THP-1 cells exhibit different cytokine expression patterns following stimulation with lipopolysaccharide. Mediators Inflamm. 2013;2013. doi: 10.1155/2013/697972 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Aldo PB, Craveiro V, Guller S, Mor G. Effect of culture conditions on the phenotype of THP-1 monocyte cell line. Am J Reprod Immunol. 2013;70: 80–86. doi: 10.1111/aji.12129 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines. Immunity. 2014;41: 14–20. doi: 10.1016/j.immuni.2014.06.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Menck K, Behme D, Pantke M, Reiling N, Binder C, Pukrop T, et al. Isolation of human monocytes by double gradient centrifugation and their differentiation to macrophages in Teflon-coated cell culture bags. J Vis Exp. 2014. [cited 13 Aug 2020]. doi: 10.3791/51554 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Mukundan L, Bishop GA, Head KZ, Zhang L, Wahl LM, Suttles J. TNF Receptor-Associated Factor 6 Is an Essential Mediator of CD40-Activated Proinflammatory Pathways in Monocytes and Macrophages. J Immunol. 2005;174: 1081–1090. doi: 10.4049/jimmunol.174.2.1081 [DOI] [PubMed] [Google Scholar]
  • 35.Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods. 2001. doi: 10.1006/meth.2001.1262 [DOI] [PubMed] [Google Scholar]
  • 36.Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med. 1992;176: 287–292. doi: 10.1084/jem.176.1.287 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Mantovani A, Sica A, Locati M. Macrophage polarization comes of age. Immunity. 2005. pp. 344–346. doi: 10.1016/j.immuni.2005.10.001 [DOI] [PubMed] [Google Scholar]
  • 38.Davis MJ, Tsang TM, Qiu Y, Dayrit JK, Freij JB, Huffnagle GB, et al. Macrophage M1/M2 polarization dynamically adapts to changes in cytokine microenvironments in Cryptococcus neoformans infection. MBio. 2013;4. doi: 10.1128/mBio.00264-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Griffoni C, Neidhart B, Yang K, Groeber-Becker F, Maniura-Weber K, Dandekar T, et al. In vitro skin culture media influence the viability and inflammatory response of primary macrophages. Sci Reports 2021 111. 2021;11: 1–11. doi: 10.1038/s41598-021-86486-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Garelnabi M, Taylor-Smith LM, Bielska E, Hall RA, Stones D, May RC. Quantifying donor-to-donor variation in macrophage responses to the human fungal pathogen Cryptococcus neoformans. PLoS One. 2018;13. doi: 10.1371/JOURNAL.PONE.0194615 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Vogel DYS, Glim JE, Stavenuiter AWD, Breur M, Heijnen P, Amor S, et al. Human macrophage polarization in vitro: Maturation and activation methods compared. Immunobiology. 2014;219: 695–703. doi: 10.1016/j.imbio.2014.05.002 [DOI] [PubMed] [Google Scholar]
  • 42.Kim S, Miller BJ, Stefanek ME, Miller AH. Inflammation-induced activation of the indoleamine 2,3-dioxygenase pathway: Relevance to cancer-related fatigue. Cancer. John Wiley and Sons Inc.; 2015. pp. 2129–2136. doi: 10.1002/cncr.29302 [DOI] [PubMed] [Google Scholar]
  • 43.Wang XF, Wang HS, Wang H, Zhang F, Wang KF, Guo Q, et al. The role of indoleamine 2,3-dioxygenase (IDO) in immune tolerance: Focus on macrophage polarization of THP-1 cells. Cell Immunol. 2014;289: 42–48. doi: 10.1016/j.cellimm.2014.02.005 [DOI] [PubMed] [Google Scholar]
  • 44.Zhao Q, Kuang D-M, Wu Y, Xiao X, Li X-F, Li T-J, et al. Activated CD69 + T Cells Foster Immune Privilege by Regulating IDO Expression in Tumor-Associated Macrophages. J Immunol. 2012;188: 1117–1124. doi: 10.4049/jimmunol.1100164 [DOI] [PubMed] [Google Scholar]
  • 45.Iqbal S, Kumar A. Characterization of In vitro Generated Human Polarized Macrophages. J Clin Cell Immunol. 2015;06: 380. doi: 10.4172/2155-9899.1000380 [DOI] [Google Scholar]
  • 46.De Vries JE. Immunosuppressive and anti-inflammatory properties of interleukin 10. Ann Med. 1995;27: 537–541. doi: 10.3109/07853899509002465 [DOI] [PubMed] [Google Scholar]
  • 47.Groux H, Bigler M, de Vries JE, Roncarolo MG. Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J Immunol. 1998;160. [PubMed] [Google Scholar]
  • 48.De Waal Malefyt R, Abrams J, Bennett B, Figdor CG, De Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991;174: 1209–1220. doi: 10.1084/jem.174.5.1209 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Ambarus CA, Krausz S, van Eijk M, Hamann J, Radstake TRDJ, Reedquist KA, et al. Systematic validation of specific phenotypic markers for in vitro polarized human macrophages. J Immunol Methods. 2012;375: 196–206. doi: 10.1016/j.jim.2011.10.013 [DOI] [PubMed] [Google Scholar]
  • 50.Chroneos Z, Shepherd VL. Differential regulation of the mannose and SP-A receptors on macrophages. Am J Physiol—Lung Cell Mol Physiol. 1995;269. doi: 10.1152/ajplung.1995.269.6.L721 [DOI] [PubMed] [Google Scholar]
  • 51.Jaguin M, Houlbert N, Fardel O, Lecureur V. Polarization profiles of human M-CSF-generated macrophages and comparison of M1-markers in classically activated macrophages from GM-CSF and M-CSF origin. Cell Immunol. 2013;281: 51–61. doi: 10.1016/j.cellimm.2013.01.010 [DOI] [PubMed] [Google Scholar]
  • 52.Krausgruber T, Blazek K, Smallie T, Alzabin S, Lockstone H, Sahgal N, et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol 2011 123. 2011;12: 231–238. doi: 10.1038/ni.1990 [DOI] [PubMed] [Google Scholar]
  • 53.Novak ML, Weinheimer-Haus EM, Koh TJ. Macrophage activation and skeletal muscle healing following traumatic injury. J Pathol. 2014;232: 344–355. doi: 10.1002/path.4301 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Finlin BS, Zhu B, Starnes CP, McGehee RE, Peterson CA, Kern PA. Regulation of Thrombospondin-1 expression in alternatively activated macrophages and adipocytes: role of cellular crosstalk and omega-3 fatty acids. J Nutr Biochem. 2013;24: 1571. doi: 10.1016/j.jnutbio.2013.01.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Liu Y, Beyer A, Aebersold R. On the Dependency of Cellular Protein Levels on mRNA Abundance. Cell. 2016;165: 535–550. doi: 10.1016/j.cell.2016.03.014 [DOI] [PubMed] [Google Scholar]
  • 56.Anisimova AS, Meerson MB, Gerashchenko M V., Kulakovskiy I V., Dmitriev SE, Gladyshev VN. Multifaceted deregulation of gene expression and protein synthesis with age. Proc Natl Acad Sci U S A. 2020;117: 15581–15590. doi: 10.1073/pnas.2001788117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Wang YC, Peterson SE, Loring JF. Protein post-translational modifications and regulation of pluripotency in human stem cells. Cell Res. 2014;24: 143–160. doi: 10.1038/cr.2013.151 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Alain Haziot

Transfer Alert

This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.

1 Oct 2021

PONE-D-21-23747Effect of stimulation time on the expression of human macrophage polarization markersPLOS ONE

Dear Dr. Sag,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The manuscript addresses an important question and results presented are of interest. However, a number of issues have been raised by the Reviewers, and need to be all addressed. In particular, a more comprehensive phenotype of differentiated macrophages should be provided in order to clearly determine the type and level of cell differentiation.

Please submit your revised manuscript by January 31, 2022. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Alain Haziot, M.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Purcu and colleagues used primary human monocyte-derived macrophages to determine the optimal time points for analyses of various M1, M2a and M2c polarization markers following in vitro stimulation of MDM.

The authors showed that polarization markers that delineate M1, M2a and M2c MDM were optimally expressed at different times post-stimulation. Results are of interest, addressing important questions regarding the optimal time to use in vitro polarized M1, M2a and M2c MDM. Experiments are generally well-performed. The manuscript is well-written and easy to read, and the figures are generally well-presented. I have one major comment.

Major comment

The figure legends for all 3 figures highlight that the data in each of the figures is derived from 3 donors. The issue of donor-donor variability is widely reported and therefore, the authors should present the data for each donor separately. This would show if “the optimal time points for the analysis of the expression of the main M1, M2a, and M2c polarization markers” is consistent for each donor, and the most convincing way to support the conclusions of the authors.

Reviewer #2: This article was designed by the authors to identify the best time of activation (from 4h to 72h) to characterize specific markers of human monocyte-derived macrophages polarized into M1, M2a and M2c by using RT-PCR for mRNA expression analysis, flow cytometry to characterize membrane specific markers and ELISA to quantify secretion of cytokines/chemokines.

The data are informative but are not enough ambitious.

Determine the best time of polarization is necessary and the authors did it but I suggest adding more markers per polarization profile. In fact, it will be interesting to have the data for the same markers at the mRNA and secreted markers ; It was done only for TNFa in M1 MDM.

Moreover, some markers are not so specific to a type of polarization (CD206 for example) that is why it will be informative to have the expression in both the 3 phenotypes. In fact, to characterize a population of MDM from patients for example, we need to be confident with the difference of expression between subtypes.

The authors should modulate their conclusion, because the most important thing is to know if a marker is up or not and not so much how fold increased it is, except if we compared it to an another polarization profile ; that was not done here. In fcat, is more important to known when the marker is not expressed than is significantly expressed but lower.

I suggest to precise the % of viability cells after 24h, 48h and 72H, as LPS at 100 ng/ml may be strong for M1 MDM. These data can be extracted form flow cytometry analysis since a fixable viability kit was used. The pic of isotype control should appear on flow cytometry graph.

Student’t test cannot be used for the figures but an Anova test.

Please corrected page 10, paragraph 3.3 : “analyzed by flow cytometry” replace by “analyzed by ELISA”.

Please precise the number of replicate, it is not clear : if data are representative of 2 experiments, statistics cannot be done.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Review PlosOne_macro time.docx

PLoS One. 2022 Mar 14;17(3):e0265196. doi: 10.1371/journal.pone.0265196.r002

Author response to Decision Letter 0


30 Jan 2022

Response to the Reviewers, PLOS ONE

We were pleased to find that the reviewers and the editors thought that our manuscript entitled “Effect of stimulation time on the expression of human macrophage polarization markers” by Purcu et al., was of interest and we thank you for the positive comments that we received and for giving the opportunity to submit a revised version. We also appreciate the editor’s and the reviewers' time and effort in providing valuable feedback that has helped us enhance the manuscript.

Please find the revised manuscript attached, which incorporates the reviewers' and editor's suggestions and highlights the significant changes in the text in yellow. Here is our point-by-point response to the concerns raised.

We believe that we have adequately addressed all the concerns raised by the academic editor and the reviewers, and hope that our revised manuscript is now suitable for publication in PLOS ONE.

Academic Editor:

The manuscript addresses an important question and results presented are of interest. However, a number of issues have been raised by the Reviewers, and need to be all addressed. In particular, a more comprehensive phenotype of differentiated macrophages should be provided in order to clearly determine the type and level of cell differentiation.

Response: We thank the editor for this valuable comment. We would like to emphasize that our goal was to determine the optimum stimulation time for the expression of established M1/M2 polarization markers, rather than to specify the type and level of cell differentiation. We believe, we incorporated the most important and widely used polarization markers for each macrophage cell type. However, as the reviewers suggested, all the secreted markers that had been previously analyzed by ELISA were also analyzed at mRNA level by qPCR. The data for “IL1β and IL12A” as M1 Markers; “IL10” as M2a marker; “TGFβ” as M2c marker were incorporated in the new Fig 1 (D, E, K and N). The Results and Discussion sections were modified accordingly.

Reviewer #1:

Purcu and colleagues used primary human monocyte-derived macrophages to determine the optimal time points for analyses of various M1, M2a, and M2c polarization markers following in vitro stimulation of MDM.

The authors showed that polarization markers that delineate M1, M2a, and M2c MDM were optimally expressed at different times post-stimulation. Results are of interest, addressing important questions regarding the optimal time to use in vitro polarized M1, M2a, and M2c MDM. Experiments are generally well-performed. The manuscript is well-written and easy to read, and the figures are generally well-presented. I have one major comment.

Major comment

1- The figure legends for all 3 figures highlight that the data in each of the figures are derived from 3 donors. The issue of donor-donor variability is widely reported and therefore, the authors should present the data for each donor separately. This would show if “the optimal time points for the analysis of the expression of the main M1, M2a, and M2c polarization markers” is consistent for each donor, and the most convincing way to support the conclusions of the authors.

Response 1

We thank the reviewer for this excellent suggestion. We incorporated the new supplementary figures (S1 Fig, S2 Fig and S3 Fig) that shows for each donor separately the changes over time of the expression of the analysed M1, M2a, and M2c polarization markers. This allows now to evaluate the donor-to-donor variability for each marker and each time point.

Reviewer #2:

This article was designed by the authors to identify the best time of activation (from 4h to 72h) to characterize specific markers of human monocyte-derived macrophages polarized into M1, M2a, and M2c by using RT-PCR for mRNA expression analysis, flow cytometry to characterize membrane specific markers and ELISA to quantify secretion of cytokines/chemokines.

The data are informative but are not enough ambitious.

1- Determine the best time of polarization is necessary and the authors did it but I suggest adding more markers per polarization profile. In fact, it will be interesting to have the data for the same markers at the mRNA and secreted markers; It was done only for TNF in M1 MDM.

Response 1

We thank the reviewer for this excellent suggestion. In this revised manuscript, all the secreted markers that had been previously analyzed only by ELISA were now also analyzed at mRNA level by qPCR. The data for “IL1β and IL12A” as M1 Markers; “IL10” as M2a marker; “TGFβ” as M2c marker were incorporated in the new Fig 1 (D, E, K and N). The Results and Discussion sections were modified accordingly.

2- Moreover, some markers are not so specific to a type of polarization (CD206 for example) that is why it will be informative to have the expression in both the 3 phenotypes. In fact, to characterize a population of MDM from patients, for example, we need to be confident with the difference of expression between subtypes.

Response 2

We thank the reviewer for this valuable recommendation. As suggested, the expression of the M2 markers were analyzed in each macrophage subtypes by flow cytometry. In accordance with the literature (Stein et al. 1992; Gordon 2003; Mantovani et al. 2004, 2005; Davis et al. 2013; Murray et al. 2014), the strong upregulation of CD206 on M2a macrophages was not seen on M1 or M2c macrophages. Likewise, the expression of the M2c marker “CD163” was not increased on M1 or M2a macrophages. Therefore, we conclude that the M2 markers we chose for each macrophage subtype were appropriate. We incorporated these data in the new supplementary figure (S4 Fig) and modified the Results section accordingly.

3- The authors should modulate their conclusion, because the most important thing is to know if a marker is up or not and not so much how fold increased it is, except if we compared it to another polarization profile; that was not done here. In fact, is more important to know when the marker is not expressed than is significantly expressed but lower.

We thank the reviewer for this comment. We agree with the reviewer that the ability to detect a polarization marker is essential to define the macrophage subsets. The data on significant differences in expression are provided throughout our manuscript. Obviously, the stronger a marker is expressed, the easier it is to identify a given subset. Therefore, providing the fold-changes offers the readers the possibility to select the optimal time point for their experimental needs. As supporting the experimental design of our readers is the main goal of our manuscript we feel that taking this aspect out would weaken the usability of our data for the readers. However, we understand the reviewer’s concern and modified our Table 1 to specify a range for the suggested stimulation times for all markers.

4- I suggest to precise the % of viable cells after 24h, 48h, and 72H, as LPS at 100 ng/ml may be strong for M1 MDM. These data can be extracted from flow cytometry analysis since a fixable viability kit was used.

Response 4

We thank the reviewer for this comment. As the reviewer suggested, we re-analyzed our flow cytometry data to determine the percentages of the viable cells after 100 ng/ml LPS + 10 ng/ml IFN� treatment. Statistical analysis showed that there is no significant difference between the 100 ng/ml LPS + 10 ng/ml IFN� treated and untreated cells at 24, 48 and 72 h, as shown below. We incorporated this information in the “Polarization of human MDMs” part of the Materials and Methods section as “The viability of the LPS+ IFN� treated human MDMs was analyzed by flow cytometry and was over 92% for all time points.”

5- The pic of isotype control should appear on the flow cytometry graph.

Response 5

We thank the reviewer for this comment. We view isotype controls critically and follow other experts in the field with a similar opinion. Investigators chose, among several antibody options, usually the isotype control that yields the lowest background, basically obliterating by this selection the indented effect.

“Isotype controls have a long history in flow cytometry and are meant to account for nonspecific staining of an antibody of a particular isotype conjugated to a particular fluorochrome. However, even when the control antibody is isotype matched to the test antibody, there are two main limitations to the usefulness of this type of control. The first limitation is that individual antibody conjugates have various levels of background staining, depending upon their specificity, concentration, degree of aggregation, and fluorophore: antibody ratio, among other variables. It is thus a hit-or-miss prospect to find an isotype control that truly matches the background staining of a particular test antibody. And, remembering that we are using the isotype control to help us define the true level of background staining, this becomes a circular proposition.” (Maeker & Trotter, Cytometry 2006, PMID: 16888771)

Similar to Maeker & Trotter, we do believe that biological controls are preferable.

“For example, in stimulation assays, the unstimulated (or irrelevantly stimulated) sample usually provides the best means to distinguish positive from negative events” (Maeker & Trotter, Cytometry 2006, PMID: 16888771)

Isotype controls are often used in cases were such a biological control might be misleading. Therefore, we feel confident that using unstimulated cells as negative control is a valid and stringent control in this manuscript.

6- Student’t test cannot be used for the figures but an Anova test.

Response 6

As the reviewer suggested, statistical analyses were performed with Anova test. The Methods section and the figure legends were modified accordingly in this revised manuscript. The analysis was performed by a bioistatician, who is now added as a coauthor to the revised manuscript.

7- Please correct page 10, paragraph 3.3 : “analyzed by flow cytometry” replace by “analyzed by ELISA”.

Response 7

We apologize for this omission. Page 14, paragraph 4.3: “analyzed by flow cytometry” is replaced by the correct phrase “analyzed by ELISA” at lane 301. We thank the reviewer for their attention.

8- Please precise the number of replicate, it is not clear : if data are representative of 2 experiments, statistics cannot be done.

Response 8

We apologize for the unclear phrasing. In the revised manuscript, we corrected the phrase as “Data shown are mean ± SEM of biological replicates of 3 independent donors” in both the Methods section and the figure legends. We thank the reviewer for pointing this out to us.

REFERENCES:

Davis MJ, Tsang TM, Qiu Y, Dayrit JK, Freij JB, Huffnagle GB, et al. Macrophage M1/M2 polarization dynamically adapts to changes in cytokine microenvironments in Cryptococcus neoformans infection. MBio [Internet]. 2013 [cited 2021 Oct 25];4(3). Available from: https://journals.asm.org/journal/mbio

Gordon S. Alternative activation of macrophages [Internet]. Vol. 3, Nature Reviews Immunology. Nature Publishing Group; 2003 [cited 2020 Aug 19]. p. 23–35. Available from: https://www.nature.com/articles/nri978

Mantovani A, Sica A, Locati M. Macrophage polarization comes of age. Vol. 23, Immunity. 2005. p. 344–6.

Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization [Internet]. Vol. 25, Trends in Immunology. Oxford University Press, Oxford; 2004 [cited 2017 Sep 7]. p. 677–86. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15530839

Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines. Immunity [Internet]. 2014 Aug 17 [cited 2020 Aug 26];41(1):14–20. Available from: http://dx.doi.org/10.1016/j.immuni.2014.06.008

Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med [Internet]. 1992 Jul 1 [cited 2021 Oct 25];176(1):287–92. Available from: http://rupress.org/jem/article-pdf/176/1/287/1102739/287.pdf

Attachment

Submitted filename: Response to reviewers.docx

Decision Letter 1

Alain Haziot

22 Feb 2022

PONE-D-21-23747R1Effect of stimulation time on the expression of human macrophage polarization markersPLOS ONE

Dear Dr. Sag,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

A couple of minor comments need to be addressed. Your revised manuscript would then go through an expedited review.

Please submit your revised manuscript by March 7, 2022. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Alain Haziot, M.D.

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: The authors have addressed my recommendations

I have some minors recommendations:

- I suggest to add in the table 1 the new data on Il-10 and on TGF-b mRNA levels in M2a and M2c macrophages respectively

- see the reference of Actin B primers lines 168 an 173.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Mar 14;17(3):e0265196. doi: 10.1371/journal.pone.0265196.r004

Author response to Decision Letter 1


24 Feb 2022

Response to the Reviewers, PLOS ONE

We were pleased to find that the reviewers and the editors thought that our manuscript entitled “Effect of stimulation time on the expression of human macrophage polarization markers” by Purcu et al., was of interest and that we addressed all of their concerns raised in our revised manuscript. We thank you for giving us the opportunity to submit a revised version. We also appreciate the editor’s and the reviewers' time and effort in providing valuable feedback that has helped us to enhance the manuscript.

Please find the revised manuscript attached, which incorporates the reviewers’ minor comments and highlights the significant changes in the text in yellow. Please find our point-by-point response to the comments below.

We believe that we have adequately addressed all the concerns raised by the reviewers, and hope that our revised manuscript is now suitable for publication in PLOS ONE.

Reviewer #2:

1- I suggest to add in the table 1 the new data on Il-10 and on TGF-b mRNA levels in M2a and M2c macrophages respectively

Response 1

We thank the reviewer for this comment. We added information on IL-10 in M2a macrophages and TGFβ in M2c macrophages at mRNA level to the revised Table 1.

2- See the reference of Actin B primers lines 168 an 173.

Response 2

We thank the reviewer for this comment and apologize for the confusion. The Actin B primers mentioned in lines 168 and 173 have different reference ID’s as they are primers from different manufacturers. In the first version of the manuscript, all the real time PCR experiments were performed using the RealTime ready Single Assays by Roche. However, as these assays were later discontinued, for the revision we had to use a different assay with a different reference ID.

Attachment

Submitted filename: 20220224_Response to reviewers.docx

Decision Letter 2

Alain Haziot

28 Feb 2022

Effect of stimulation time on the expression of human macrophage polarization markers

PONE-D-21-23747R2

Dear Dr. Sag,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Alain Haziot, M.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Alain Haziot

4 Mar 2022

PONE-D-21-23747R2

Effect of stimulation time on the expression of human macrophage polarization markers

Dear Dr. Sag:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Alain Haziot

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Statistical analyses for M1, M2a and M2c markers at mRNA level in polarized macrophages.

    Expression of the indicated markers at the time points shown were compared by repeated measures ANOVA, * p < 0.05; ** p < 0.01; *** p < 0.001. ns, not significant; US, unstimulated.

    (PDF)

    S2 Table. Statistical analyses for M1, M2a and M2c surface markers in polarized macrophages.

    Expression of the indicated markers at the time points shown were compared by repeated measures ANOVA, * p < 0.05; ** p < 0.01; *** p < 0.001. ns, not significant; US, unstimulated.

    (PDF)

    S3 Table. Statistical analyses for M1, M2a and M2c cytokines in polarized macrophages.

    Expression of the indicated markers at the time points shown were compared by repeated measures ANOVA, * p < 0.05; ** p < 0.01; *** p < 0.001. ns, not significant; US, unstimulated.

    (PDF)

    S1 Fig. Time-dependent changes in the expression of macrophage polarization markers at the mRNA level for each donor.

    (TIF)

    S2 Fig. Time-dependent changes in the expression of macrophage polarization markers at the protein level for each donor.

    (TIF)

    S3 Fig. Time-dependent changes in cytokine production for each donor.

    (TIF)

    S4 Fig. Time depended changes in the expression of M2 markers in M1, M2a and M2c macrophages analysed by flow cytometry.

    Summary data shown are mean ± SEM of biological replicates of 3 independent donors. Polarized macrophages (M1, M2a, or M2c) at all time points were compared with unstimulated (US) M0 macrophages. Statistical analyses were performed with repeated measures ANOVA, * p < 0.05; ** p < 0.01; *** p < 0.001.

    (TIF)

    Attachment

    Submitted filename: Review PlosOne_macro time.docx

    Attachment

    Submitted filename: Response to reviewers.docx

    Attachment

    Submitted filename: 20220224_Response to reviewers.docx

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES